Source comparison
MOTS-c AMPK Activation: Research Protocol Comparison
Primary Endpoints AMPK phosphorylation (Western blot), ACC phosphorylation, PGC-1α mRNA Fasting glucose, insulin sensitivity (HOMA-IR), mitochondrial enzyme activity Body composition (DEXA), endurance capacity, muscle fiber typing, RER measurements Acute studi
This comparison does not assign a generated winner or score.
- Primary Endpoints
- AMPK phosphorylation (Western blot), ACC phosphorylation, PGC-1α mRNA
- Fasting glucose, insulin sensitivity (HOMA-IR), mitochondrial enzyme activity
- Body composition (DEXA), endurance capacity, muscle fiber typing, RER measurements
- Acute studies prove mechanism; metabolic studies show early efficacy; phenotype studies demonstrate functional outcomes
- Typical Dosing
- Single injection, 5–10 mg
- 5–10 mg every 48–72 hours
- 10–15 mg 2–3× weekly
- Higher frequency in short studies compensates for single-dose transience; lower frequency in long studies relies on cumulative adaptation
- Sample Collection Timing
- 0.5–6 hours post-injection
- Days 7, 10, 14
- Weeks 4, 6, 8
- Mismatched timing to biological process is the most common protocol design flaw
- Expected AMPK Activation
- 2–4× baseline phosphorylation at 1 hour
- Sustained elevation detectable at trough (pre-dose) by day 10
- AMPK remains responsive but baseline shifts toward activation even without acute dosing
- Chronic MOTS-c shifts the AMPK activation set-point. Cells become metabolically primed
- Realistic Outcome Magnitude
- Enzymatic confirmation only
- 10–20% improvement in insulin sensitivity markers
- 15–25% fat mass reduction, 20–35% endurance improvement in rodent models
- Effect size scales with protocol duration. Underpowered short studies underestimate true potential